Findings of the current study are comparable with those of Cheng et al. [53], who examined the influence of the ABCG2 C421A polymorphism on imatinib plasma concentration and response in 190 Chinese CML patients. This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.